About Imarx Therapeutics
Imarx Therapeutics is a publicly listed company based in Shanghai (China) founded in 1996, and was acquired by Sycamore Entertainment in June 2010. It operates as a developing and commercialising therapeutics for vascular disorders such as stroke. Imarx Therapeutics has raised $27.01 million across 7 funding rounds from investors including HHS, Sycamore Entertainment and National Institute of Neurological Disorders and Stroke. The company has 66 employees. The company was acqui-hired. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its competitors include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Portola Pharma and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Imarx Therapeutics is developing and commercialising therapeutics for vascular disorders such as stroke. The company is using its proprietary microbubble technology to treat vascular occlusions, or blood vessel blockages, as well as the resulting ischemia, which is tissue damage caused by a reduced supply of oxygen. Its lead program was SonoLysis therapy for the treatment of acute massive pulmonary embolism or blood clots in the lungs. This therapy involves the administration of companys MRX-801 microspheres and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The company was acquired by Sycamore Films in June 2010.
- Headquarters Shanghai, China
- Employees 66
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website imarx.com
- Social LinkedIn
- Acquired by Sycamore Entertainment (Jun 2010)
- Legal Name Immuneering Corporation
- Net Profit-$56.02 M (USD)8.21as on Dec 31, 2025
- EBITDA-$58.68 M (USD)7.39as on Dec 31, 2025
- Total Equity Funding$27.01M (USD)
in 7 rounds
- Latest Funding Round$950K (USD), Grant
Aug 2007
- InvestorsHHS
& 3 more
- Employee Count66
- Acquired bySycamore Entertainment
(Jun 2010)
Funding Insights of Imarx Therapeutics
Imarx Therapeutics has successfully raised a total of $27.01M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $950 thousand completed in August 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $27.01M
- Total Rounds 7
- Last Round Grant — $950,000
- First Round $303,669
(Aug 2002)
- Investors Count 3
All 7 funding rounds of Imarx Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2007 | $950,000 | Grant | – | – | |
| May 2006 | $10,349 | Series C | – | – | – |
| Dec 2005 | $15M | Series C | – | – | – |
| Aug 2005 | $1.1M | Grant | – | – | |
| Mar 2005 | $7M | Series B | – | – | – |
| Apr 2004 | $5M | Series A | – | – | – |
| Aug 2002 | $303,669 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Imarx Therapeutics
Imarx Therapeutics has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include HHS, Sycamore Entertainment and National Institute of Neurological Disorders and Stroke.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research on neurological disorders and stroke is conducted and funded. | – | ninds.nih.gov | Bethesda, United States | |
Research on heart, lung, blood, and sleep disorders is conducted. | – | nhlbi.nih.gov | Bethesda, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Film marketing and distribution services are provided across various channels. | 1999 | sycamoreentertainment.com | Vancouver, Canada |
Investor details for Imarx Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Imarx Therapeutics
Imarx Therapeutics is a publicly listed company on the NASDAQ with ticker symbol IMRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Jul 2007
- Listed onNASDAQ: IMRX
- Listed entityImmuneering Corporation
- Exchange sectorHealth technology
- ISINUS45254E1073
- Share price$3.56 (-7.77% on the day) · 2026-10-13
- Market capitalisation$230.3M
- EPS (diluted, trailing year)$-1.03
- Volume (last session)734,912
Financials of Imarx Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$56.0M | -$58.7M |
| 2024 | – | -$61.0M | -$63.4M |
| 2023 | – | -$53.5M | -$57.6M |
| 2022 | $316,950 | -$50.5M | -$51.0M |
| 2021 | $2.1M | -$33.5M | -$33.7M |
Detailed financial statements for Imarx Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Imarx Therapeutics
5 dated milestones of Imarx Therapeutics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Imarx Therapeutics is founded.
- Funding First funding round of $304K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $950K.
- Exit Acquired by Sycamore Entertainment.
Competitors of Imarx Therapeutics
Imarx Therapeutics has 10 listed competitors in our database, 9 of them funded. They include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Portola Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. |
Detailed competitors of Imarx Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Imarx Therapeutics
Websites that share an audience with Imarx Therapeutics (imarx.com).
Websites whose visitors overlap most with Imarx Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
edap-hifu.com | edap-hifu.com | 100% | – | – | – |
ulthera.com | ulthera.com | 100% | – | – | – |
ultrasonics.org | ultrasonics.org | 100% | – | #6,594,017 | – |
utlltd.co.uk | utlltd.co.uk | 100% | – | – | – |
focused-ultrasound.org | focused-ultrasound.org | 100% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Imarx Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Imarx Therapeutics (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Imarx Therapeutics
Complete news archive for Imarx Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Imarx Therapeutics
Imarx Therapeutics was founded in 1996 and raised its 1st funding round 6 years after it was founded.
Imarx Therapeutics is headquartered in Shanghai, China.
Imarx Therapeutics is a funded company, having raised a total of $27.01M across 7 funding rounds to date. The company's 1st funding round was a Grant of $303.67K, raised on Aug 2002.
Imarx Therapeutics has 66 employees.
Imarx Therapeutics is developing and commercialising therapeutics for vascular disorders such as stroke. The company is using its proprietary microbubble technology to treat vascular occlusions, or blood vessel blockages, as well as the resulting ischemia, which is tissue damage caused by a reduced supply of oxygen. Its lead program was SonoLysis therapy for the treatment of acute massive pulmonary embolism or blood clots in the lungs. This therapy involves the administration of companys MRX-801 microspheres and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The company was acquired by Sycamore Films in June 2010.
Imarx Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Yes, Imarx Therapeutics is publicly traded on NASDAQ under the ticker symbol IMRX.
Imarx Therapeutics has 4 investors. Key investors include HHS, Sycamore Entertainment, National Institute of Neurological Disorders and Stroke, and National Heart, Lung, and Blood Institute.
Yes. Imarx Therapeutics was acquired by Sycamore Entertainment in June 2010.